Design Therapeutics Q2 EPS $(0.36) Beats $(0.40) Estimate
Portfolio Pulse from Benzinga Newsdesk
Design Therapeutics (NASDAQ:DSGN) reported Q2 losses of $(0.36) per share, beating the analyst consensus estimate of $(0.40) by 10 percent. However, this represents a 33.33 percent increase in losses compared to the same period last year.
August 14, 2023 | 8:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Design Therapeutics reported better than expected Q2 losses, but the losses increased significantly compared to last year.
While Design Therapeutics beat the analyst consensus estimate for Q2 losses, the fact that losses increased by 33.33% compared to the same period last year could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100